Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Account Payables (2019 - 2025)

BridgeBio Pharma's Change in Account Payables history spans 7 years, with the latest figure at $17.5 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 567.96% year-over-year to $17.5 million; the TTM value through Dec 2025 reached $26.6 million, up 1659.85%, while the annual FY2025 figure was $26.6 million, 1659.85% up from the prior year.
  • Change in Account Payables for Q4 2025 was $17.5 million at BridgeBio Pharma, up from -$7.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $17.6 million in Q1 2025 and bottomed at -$11.7 million in Q3 2021.
  • The 5-year median for Change in Account Payables is $198000.0 (2023), against an average of $1.7 million.
  • The largest YoY upside for Change in Account Payables was 5061.41% in 2024 against a maximum downside of 618.88% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at $1.5 million in 2021, then decreased by 6.59% to $1.4 million in 2022, then skyrocketed by 349.42% to $6.2 million in 2023, then tumbled by 160.56% to -$3.7 million in 2024, then skyrocketed by 567.96% to $17.5 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Change in Account Payables are $17.5 million (Q4 2025), -$7.4 million (Q3 2025), and -$1.1 million (Q2 2025).